Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kimberly Brizell

Gastroenterology Bradenton, FL Doctor of Osteopathy

NPI 1265810899 CMS profile 2782388

101 Riverfront Blvd Ste 700, Bradenton, FL 34205

Open in the dashboard

General payments

$10,433

329 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Brizell of Bradenton, FL is reported in the CMS Open Payments database as having received $10,433 across 329 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,985 61
2024 General $2,029 95
2023 General $2,043 80
2022 General $1,038 46
2021 General $763 25
2020 General $1,462 8
2019 General $1,112 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Brizell
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Kimberly Brizell were reported at $1,985. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Kimberly Brizell Gastroenterology median Middle half National median
2019 $1,112 $417 $126–$1,100 $163
2020 $1,462 $224 $74–$624 $114
2021 $763 $352 $106–$1,054 $132
2022 $1,038 $448 $129–$1,270 $149
2023 $2,043 $533 $150–$1,390 $160
2024 $2,029 $605 $160–$1,606 $164
2025 $1,985 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,505 92 payments
  2. Janssen Biotech, Inc. $1,391 47 payments
  3. CONMED Corporation $1,013 1 payment
  4. Takeda Pharmaceuticals U.S.A., Inc. $692 31 payments
  5. QOL Medical, LLC $523 18 payments
  6. Madrigal Pharmaceuticals $391 6 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $389 19 payments
  8. Pfizer Inc. $322 7 payments
  9. Gilead Sciences, Inc. $266 3 payments
  10. Daiichi Sankyo Inc. $264 3 payments
  11. Other $2,678 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,285 323 payments
  2. Consulting Fee $1,013 1 payment
  3. Education $136 5 payments
Products named General payments · program years 2019–2025
  1. SHOULDER MANUAL INSTRUMENTS $1,013 1 payment
  2. TREMFYA $830 22 payments
  3. STELARA $782 32 payments
  4. SKYRIZI $713 27 payments
  5. RINVOQ $671 32 payments
  6. ENTYVIO $628 28 payments
  7. CREON $545 28 payments
  8. Sucraid $387 13 payments
  9. HUMIRA $384 11 payments
  10. SIMPONI ARIA $378 20 payments
  11. Other $6,060 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,672

Median for Gastroenterology: 569

Drug cost

$1,063,894

Median for Gastroenterology: $104,976

Branded share of claims

26.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 23 $652,428
Creon Lipase/Protease/Amylase Brand 42 $193,338
Zenpep Lipase/Protease/Amylase Brand 11 $59,472
Linzess Linaclotide Brand 64 $43,620
Xifaxan Rifaximin Brand 12 $31,288
Budesonide Dr Budesonide Brand 53 $14,230
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 83 $13,518
Pantoprazole Sodium Generic 624 $6,854
Sucralfate Generic 78 $6,468
Mesalamine Er Mesalamine Brand 19 $6,405

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$305,303

Of which drugs: $196,943

Medicare patients

518

Average age 75

Services billed

13,446

378 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 39%
Chronic kidney disease 36%
Depression 31%
Diabetes 27%
Atrial fibrillation 26%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 12 6,300 $109,120
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 12 1,080 $26,817

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $241
$241 23 —
Sucraid
  • QOL Medical, LLC $237
$237 — —
CREON
  • AbbVie, Inc. $217
$217 42 —
TREMFYA
  • Janssen Biotech, Inc. $148
$148 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $131
$131 — 6,300

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record